SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 11, 2003
RESPIRONICS, INC.
(Exact name of Registrant as specified in its charter)
| Delaware |
000-16723 |
25-1304989 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) | ||
| 1010 Murry Ridge Lane Murrysville, Pennsylvania |
15668-8525 | |||
| (Address of Principal Executive Offices) |
(Zip Code) | |||
| 724-387-5200 |
||||
| (Registrant’s telephone number, including area code) |
Item 9. REGULATION FD DISCLOSURE.
2
Item 9. REGULATION FD DISCLOSURE.
The following information is furnished pursuant to Item 12, “Disclosure of Results of Operations and Financial Condition.”
On April 11, 2003, Respironics Inc. issued a press release announcing its plans to consolidate acquired product lines and functions. In that press release, Respironics, Inc. also reported that it expects to report earnings for the third quarter of fiscal year 2003 in line with its previous guidance. A copy of the press release is attached hereto as Exhibit 99.
Exhibits
99 Press release, dated April 11, 2003, issued by Respironics, Inc.
3
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| RESPIRONICS, INC. | ||
| /s/ Daniel J. Bevevino | ||
| Daniel J. Bevevino | ||
| Vice President, and Chief Financial and | ||
| Principal Accounting Officer | ||
| Dated: April 11, 2003 |
4
| Exhibit No. |
Description | |
| 99 |
Press release, dated April 11, 2003, issued by Respironics, Inc. |
5